The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
A Review of the Progress and Challenges of Developing a Vaccine for COVID-19
Open accessAbstract
A novel coronavirus, which has been designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first detected in December 2019 in Wuhan China and causes the highly infectious disease referred to as COVID-19. COVID-19 has now spread worldwide to become a global pandemic affecting over 24 million people as of August 26th, 2020 and claimed the life of more than 800,000 people worldwide. COVID-19 is asymptomatic for some individuals and for others it can cause symptoms ranging from flu-like to acute respiratory distress syndrome (ARDS), pneumonia and death. Although it is anticipated that an effective vaccine will be available to protect against COVID-19, at present the world is relying on social distancing and hygiene measures and repurposed drugs. There is a worldwide effort to develop an effective vaccine against SARS-CoV-2 and, as of late August 2020, there are 30 vaccines in clinical trials with over 200 in various stages of development. This review will focus on the eight vaccine candidates that entered Phase 1 clinical trials in mid-May, including AstraZeneca/Oxford's AZD1222, Moderna's mRNA-1273 and Sinovac's CoronaVac vaccines, which are currently in advanced stages of vaccine development. In addition to reviewing the different stages of vaccine development, vaccine platforms and vaccine candidates, this review also discusses the biological and immunological basis required of a SARS-CoV-2 vaccine, the importance of a collaborative international effort, the ethical implications of vaccine development, the efficacy needed for an immunogenic vaccine, vaccine coverage, the potential limitations and challenges of vaccine development. Although the demand for a vaccine far surpasses the production capacity, it will be beneficial to have a limited number of vaccines available for the more vulnerable population by the end of 2020 and for the rest of the global population by the end of 2021.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · cited 4×
“Severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) is a betacoronavirus belonging to the same group as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East Respiratory Syndrome coronavirus (MERS-CoV).”
BackgroundInfluentialThe proximal origin of SARS-CoV-2
Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C., & Garry, R. F. (2020) · Nature Medicine · doi:10.1038/s41591-020-0820-9 · Cited by 5,081
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406 · cited 10×
“There was no fever reported post the first dose but some participants in the 100 (6 out of 15; 40%) and 250 μg (8 out of 14; 57%) groups reported fever after the second dose (36).”
BackgroundMethodInfluentialThe reproductive number of COVID-19 is higher compared to SARS coronavirus
Liu, Y., Gayle, A. A., Wilder-Smith, A., & Rocklöv, J. (2020) · Journal of Travel Medicine · doi:10.1093/jtm/taaa021 · Cited by 3,192
Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis
Rodriguez-Morales, A. J., Cardona-Ospina, J. A., Gutiérrez-Ocampo, E., Villamizar-Peña, R., Holguin-Rivera, Y., Escalera-Antezana, J. P., Alvarado-Arnez, L. E., Bonilla-Aldana, D. K., Franco-Paredes, C., Henao-Martinez, A. F., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101623 · Cited by 2,542
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Developing Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30843-4 · Cited by 1,504
Development of an inactivated vaccine candidate for SARS-CoV-2
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434
Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382
Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225
Herd Immunity: Understanding COVID-19
Randolph, H. E., & Barreiro, L. B. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.012 · Cited by 1,138
Rapid COVID-19 vaccine development
Graham, B. S. (2020) · Science · doi:10.1126/science.abb8923 · Cited by 771 · cited 6×
“The S protein also undergoes a significant conformational change from a pre-fusion state to a post-fusion state, achieved by pulling and fusing the cell and viral membranes together (11).”
BackgroundInfluentialXia, S., Duan, K., Zhang, Y., Zhao, D., Zhang, H., Xie, Z., Li, X., Peng, C., Zhang, Y., Zhang, W., et al. (2020) · JAMA · doi:10.1001/jama.2020.15543 · Cited by 759
Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. (2020) · doi:10.1101/2020.03.30.20047365 · Cited by 754
Wang, H., Zhang, Y., Huang, B., Deng, W., Quan, Y., Wang, W., Xu, W., Zhao, Y., Li, N., Zhang, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.008 · Cited by 748
A strategic approach to COVID-19 vaccine R&D
Corey, L., Mascola, J. R., Fauci, A. S., & Collins, F. S. (2020) · Science · doi:10.1126/science.abc5312 · Cited by 502
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS
Dai, L., Zheng, T., Xu, K., Han, Y., Xu, L., Huang, E., An, Y., Cheng, Y., Li, S., Liu, M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.035 · Cited by 495
The hallmarks of COVID-19 disease
Tang, D., Comish, P., & Kang, R. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008536 · Cited by 447
Yu, F., Du, L., Ojcius, D. M., Pan, C., & Jiang, S. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.01.003 · Cited by 366
Making Sense of Mutation: What D614G Means for the COVID-19 Pandemic Remains Unclear
Grubaugh, N. D., Hanage, W. P., & Rasmussen, A. L. (2020) · Cell · doi:10.1016/j.cell.2020.06.040 · Cited by 353
A review of Dengvaxia®: development to deployment
Thomas, S. J., & Yoon, I.-K. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1658503 · Cited by 331
Bats as reservoirs of severe emerging infectious diseases
Han, H.-J., Wen, H.-L., Zhou, C.-M., Chen, F.-F., Luo, L.-M., Liu, J.-W., & Yu, X.-J. (2015) · Virus Research · doi:10.1016/j.virusres.2015.05.006 · Cited by 300
Liu, W., Fontanet, A., Zhang, P., Zhan, L., Xin, Z., Baril, L., Tang, F., Lv, H., & Cao, W. (2006) · The Journal of Infectious Diseases · doi:10.1086/500469 · Cited by 285
Palacios, R., Patiño, E. G., de Oliveira Piorelli, R., Conde, M. T. R. P., Batista, A. P., Zeng, G., Xin, Q., Kallas, E. G., Flores, J., Ockenhouse, C. F., et al. (2020) · Trials · doi:10.1186/s13063-020-04775-4 · Cited by 279
Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel
Adams, E. R., Ainsworth, M., Anand, R., Andersson, M. I., Auckland, K., Baillie, J. K., Barnes, E., Beer, S., Bell, J. I., Berry, T., et al. (2020) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15927.1 · Cited by 278
Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees
Jiang, S. (2020) · Nature · doi:10.1038/d41586-020-00751-9 · Cited by 174 · cited 2×
“Such a scenario may lead to the public being hesitant from accepting future vaccines (67, 68).”
BackgroundDisruption of healthcare: Will the COVID pandemic worsen non-COVID outcomes and disease outbreaks?
Barach, P., Fisher, S. D., Adams, M. J., Burstein, G. R., Brophy, P. D., Kuo, D. Z., & Lipshultz, S. E. (2020) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2020.101254 · Cited by 168
Coronavirus Disease Pandemic (COVID-19): Challenges and a Global Perspective
Malik, Y. S., Kumar, N., Sircar, S., Kaushik, R., Bhat, S., Dhama, K., Gupta, P., Goyal, K., Singh, M. P., Ghoshal, U., et al. (2020) · Pathogens · doi:10.3390/pathogens9070519 · Cited by 164
The clinical development process for a novel preventive vaccine: An overview
Singh, K., & Mehta, S. (2016) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.173187 · Cited by 147
COVID-19 human challenge studies: ethical issues
Jamrozik, E., & Selgelid, M. J. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30438-2 · Cited by 138
Sentinel surveillance of SARS-CoV-2 in wastewater anticipates the occurrence of COVID-19 casesPreprint
Chavarria-Miró, G., Anfruns-Estrada, E., Guix, S., Paraira, M., Galofré, B., Sánchez, G., Pintó, R. M., & Bosch, A. (2020) · medRxiv · doi:10.1101/2020.06.13.20129627 · Cited by 127
Han, S. (2015) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2015.4.1.46 · Cited by 115
Russia’s fast-track coronavirus vaccine draws outrage over safety
Callaway, E. (2020) · Nature · doi:10.1038/d41586-020-02386-2 · Cited by 115
COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions
Triggle, C. R., Bansal, D., Farag, E., Ding, H., & Sultan, A. A. (2020) · mSphere · doi:10.1128/msphere.00317-20 · Cited by 109
Self-citationPandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19
Sempowski, G. D., Saunders, K. O., Acharya, P., Wiehe, K. J., & Haynes, B. F. (2020) · Cell · doi:10.1016/j.cell.2020.05.041 · Cited by 109
The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world
Sharpe, H., Gilbride, C., Allen, E. R., Belij‐Rammerstorfer, S., Bissett, C., Ewer, K., & Lambe, T. (2020) · Immunology · doi:10.1111/imm.13222 · Cited by 109
Accelerating Development of SARS-CoV-2 Vaccines — The Role for Controlled Human Infection Models
Deming, M. E., Michael, N. L., Robb, M. L., Cohen, M. S., & Neuzil, K. M. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2020076 · Cited by 108
Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses
Makhoul, M., Ayoub, H. H., Chemaitelly, H., Seedat, S., Mumtaz, G. R., Al-Omari, S., & Abu-Raddad, L. J. (2020) · Vaccines · doi:10.3390/vaccines8040668 · Cited by 107
Tse, L. V., Meganck, R. M., Graham, R. L., & Baric, R. S. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00658 · Cited by 106
Multivalue ethical framework for fair global allocation of a COVID-19 vaccine
Liu, Y., Salwi, S. R., & Drolet, B. C. (2020) · Journal of Medical Ethics · doi:10.1136/medethics-2020-106516 · Cited by 106
What you always needed to know about electroporation based DNA vaccines
Gothelf, A., & Gehl, J. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22062 · Cited by 88
Human Challenge Studies in Endemic Settings: Ethical and Regulatory Issues
Jamrozik, E., & Selgelid, M. J. (2020) · SpringerBriefs in ethics · doi:10.1007/978-3-030-41480-1 · Cited by 68
Herd immunity or suppression strategy to combat COVID-19
Jung, F., Krieger, V., Hufert, F. T., & Küpper, J. ‐. (2020) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-209006 · Cited by 51
Are Genetic Vaccines the Right Weapon against COVID-19?
Conforti, A., Marra, E., Roscilli, G., Palombo, F., Ciliberto, G., & Aurisicchio, L. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.007 · Cited by 17
The Improbability of the Rapid Development of a Vaccine for SARS-CoV-2
Morris, K. V. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.005 · Cited by 14
Coronavirus vaccine developers wary of errant antibodies
Garber, K. (2020) · Nature Biotechnology · doi:10.1038/d41587-020-00016-w · Cited by 11
Coronavirus vaccines leap through safety trials — but which will work is anybody’s guess
Callaway, E. (2020) · Nature · doi:10.1038/d41586-020-02174-y · Cited by 11
Cited by
COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates
Sallam, M. (2021) · Vaccines · doi:10.3390/vaccines9020160 · Cited by 2,128
“Vaccine cost, effectiveness and duration of protection appear as important factors to achieve such a goal [83,90,91].”
BackgroundHall, V. J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., Wellington, E., Stowe, J., Gillson, N., Atti, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00790-x · Cited by 767
Sallam, M., Dababseh, D., Eid, H., Al-Mahzoum, K., Al-Haidar, A., Taim, D., Yaseen, A., Ababneh, N. A., Bakri, F. G., & Mahafzah, A. (2021) · Vaccines · doi:10.3390/vaccines9010042 · Cited by 675
Mohammed, I., Nauman, A., Paul, P., Ganesan, S., Chen, K.-H., Jalil, S. M. S., Jaouni, S. H., Kawas, H., Khan, W. A., Vattoth, A. L., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2027160 · Cited by 406
Safiabadi Tali, S. H., LeBlanc, J. J., Sadiq, Z., Oyewunmi, O. D., Camargo, C., Nikpour, B., Armanfard, N., Sagan, S. M., & Jahanshahi-Anbuhi, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00228-20 · Cited by 405
Metadata
- Authors
- Sharma, O., Sultan, A. A., Ding, H., & Triggle, C. R.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-10-14
- Volume
- 11
- Pages
- 585354-585354
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3092705824
- Cited by
- 546
- References
- 56
- FWCI
- 13.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.